Using advanced MRI to guide chemotherapy for pancreatic cancer
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
This study is testing whether using advanced MRI to guide chemotherapy can help shrink pancreatic tumors so they can be surgically removed.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Ohio State University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Indianapolis, Indiana and 1 other locations) |
| Trial ID | NCT06173310 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of chemotherapy guided by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in reducing borderline resectable pancreatic tumors, potentially making them operable. The research team at the University of Alabama at Birmingham has been exploring DCE-MRI for over a decade, utilizing its ability to assess blood flow in tumors as an indicator of treatment response. By comparing this innovative approach to conventional methods, the study seeks to improve surgical outcomes for patients with this challenging diagnosis.
Who should consider this trial
Good fit: Ideal candidates include adults aged 19 and older with newly diagnosed and untreated borderline resectable pancreatic cancer.
Not a fit: Patients with a history of prior treatment for pancreatic cancer or those with contraindications to MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the chances of surgical resection for patients with borderline resectable pancreatic cancer.
How similar studies have performed: Other studies utilizing advanced imaging techniques for cancer treatment have shown promising results, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age 19 years or older). * Patients with newly diagnosed and untreated borderline resectable pancreatic cancer. * Patients with signed informed consent. Exclusion Criteria: * Any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer. * Participants with safety contraindications to MRI examination (determined by standard clinical screening). * Participants who are pregnant, lactating or are planning to become pregnant during the study. * Participants who are planning to father a child during the study.
Where this trial is running
Indianapolis, Indiana and 1 other locations
- Indiana University Medical Center — Indianapolis, Indiana, United States (Recruiting)
- The Ohio State University — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Harrison Kim, PhD — Ohio State University
- Study coordinator: Tamara Stein, MPH
- Email: Tamara.Stein@osumc.edu
- Phone: 614-293-8315
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.